0 Comments
0 Shares
411 Views
0 Reviews
Search
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
Atopic Dermatitis Market: How Are New Biologic Mechanisms Expanding AD Treatment Options?Novel biologic mechanisms for atopic dermatitis — tralokinumab (Adbry), lebrikizumab (Ebglyss), nemolizumab, and pipeline biologics targeting IL-13 specifically, IL-31 itch signaling, TSLP, and OX40L — represent the diversification of AD biologic mechanisms beyond the established IL-4/IL-13 dual blockade of dupilumab, with the Atopic Dermatitis Market reflecting biologic diversity...0 Comments 0 Shares 546 Views 0 Reviews